Revisiting Bacille Calmette-Guérin revaccination strategies: timing of immunization, Mycobacterium tuberculosis and non-tuberculous mycobacteria infections, strain potency and standardization of randomized controlled trials

被引:3
作者
Gong, Wenping [1 ,6 ]
Du, Jingli [2 ]
Aspatwar, Ashok [3 ]
Zhuang, Li [1 ,4 ]
Zhao, Yanlin [5 ]
机构
[1] Peoples Liberat Army Gen Hosp, Med Ctr 8, Senior Dept TB, Beijing Key Lab New Techn TB Diag & Treatment,Inst, Beijing, Peoples R China
[2] Peoples Liberat Army Gen Hosp, Med Ctr 8, Senior Dept TB, TB Control Team, Beijing, Peoples R China
[3] Tampere Univ, Fac Med & Hlth Technol, Tampere, Finland
[4] Hebei North Univ, Zhangjiakou, Peoples R China
[5] Chinese Ctr Dis Control & Prevent, Natl Ctr TB Control & Prevent, Beijing 102206, Peoples R China
[6] Peoples Liberat Army Gen Hosp, Med Ctr 8, 17 Heishanhu Rd, Beijing 100091, Peoples R China
来源
CLINICAL AND TRANSLATIONAL DISCOVERY | 2024年 / 4卷 / 03期
关键词
Bacille Calmette-Gu & eacute; rin; efficacy; non-tuberculous mycobacteria; randomized controlled trial; tuberculosis; SCHOOL-AGED CHILDREN; BCG REVACCINATION; IMMUNE-RESPONSE; VACCINE STRAIN; PROTECTION; BRAZIL;
D O I
10.1002/ctd2.301
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The persistent threat of tuberculosis (TB) on a global scale hasprompted a reevaluation of preventive strategies, with a particular focus onthe Bacille Calmette-Gu & eacute;rin (BCG) vaccine's role in revaccination. Theresurgence underscores an urgent need for enhanced measures, prompting acritical examination of BCG revaccination strategies. Drawing from the researchof Paulo Cesar Pereira dos Santos and a synthesis of randomized controlledtrials (RCTs), this review identifies key considerations for refining BCGrevaccination's efficacy against Mycobacterium tuberculosis (MTB) andTB. The main body of this review integrates four principal domains essentialfor optimizing BCG revaccination: the timing of revaccination, the assessmentof various BCG strains, the evaluation of the vaccine's effectiveness on MTBand non-tuberculous mycobacteria (NTM) strains, and the enhancement of RCTmethodologies. Determining the optimal revaccination timing is paramount forbolstering immunity, especially in regions with high TB prevalence. Theanalysis of different BCG strains provides insights into strain-specificimmunogenicity, informing vaccine deployment strategies. Additionally,understanding the vaccine's impact on a range of mycobacterial infections iscrucial for its broader application in various microbial contexts. The reviewemphasizes the refinement of RCT designs to ensure robust and consistentoutcomes, facilitating the reproducibility of results in diverse settings. Itproposes a strategy that not only suggests modifications to revaccinationpractices to increase global TB prevention effectiveness but also calls forcontinuous research to improve BCG revaccination methodologies. The paperadvocates for a standardized, evidence-driven approach to global TB preventionthat takes into account regional epidemiological differences. In conclusion,this review significantly contributes to the discourse on TB prevention,advocating for evidence-based, standardized approaches that could potentiallytransform the role of BCG revaccination in global TB prevention efforts. Thefindings support current initiatives aimed at developing policies based onsolid evidence, ensuring the scientific integrity and practical relevance ofBCG revaccination strategies.
引用
收藏
页数:8
相关论文
共 20 条
[1]   Genomic expression catalogue of a global collection of BCG vaccine strains show evidence for highly diverged metabolic and cell-wall adaptations [J].
Abdallah, Abdallah M. ;
Hill-Cawthorne, Grant A. ;
Otto, Thomas D. ;
Coll, Francesc ;
Guerra-Assuncao, Jose Afonso ;
Gao, Ge ;
Naeem, Raeece ;
Ansari, Hifzur ;
Malas, Tareq B. ;
Adroub, Sabir A. ;
Verboom, Theo ;
Ummels, Roy ;
Zhang, Huoming ;
Panigrahi, Aswini Kumar ;
McNerney, Ruth ;
Brosch, Roland ;
Clark, Taane G. ;
Behr, Marcel A. ;
Bitter, Wilbert ;
Pain, Arnab .
SCIENTIFIC REPORTS, 2015, 5
[2]   The success and failure of BCG - implications for a novel tuberculosis vaccine [J].
Andersen, P ;
Doherty, TM .
NATURE REVIEWS MICROBIOLOGY, 2005, 3 (08) :656-662
[3]   Tuberculosis vaccine BCG: the magical effect of the old vaccine in the fight against the COVID-19 pandemic [J].
Aspatwar, Ashok ;
Gong, Wenping ;
Wang, Shuyong ;
Wu, Xueqiong ;
Parkkila, Seppo .
INTERNATIONAL REVIEWS OF IMMUNOLOGY, 2022, 41 (02) :283-296
[4]   Evidence of an effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: Second report of the BCG-REVAC cluster-randomised trial [J].
Barreto, Mauricio L. ;
Pereira, Susan M. ;
Pilger, Daniel ;
Cruz, Alvaro A. ;
Cunha, Sergio S. ;
Sant'Anna, Clemax ;
Ichihara, Maria Y. ;
Genser, Bernd ;
Rodrigues, Laura C. .
VACCINE, 2011, 29 (31) :4875-4877
[5]   A historical and molecular phylogeny of BCG strains [J].
Behr, MA ;
Small, PM .
VACCINE, 1999, 17 (7-8) :915-922
[6]  
Bierrenbach Ana L., 2003, Rev Panam Salud Publica, V13, P285, DOI 10.1590/S1020-49892003000400003
[7]   VARIATION IN PROTECTION BY BCG - IMPLICATIONS OF AND FOR HETEROLOGOUS IMMUNITY [J].
FINE, PEM .
LANCET, 1995, 346 (8986) :1339-1345
[8]  
Glynn Judith R, 2021, Lancet Glob Health, V9, pe1451, DOI 10.1016/S2214-109X(21)00309-0
[9]   Optimising the vaccine strategy of BCG, ChAdOx185A, and MVA85A for tuberculosis control [J].
Gong, Wenping ;
Du, Jingli .
LANCET INFECTIOUS DISEASES, 2024, 24 (03) :224-226
[10]   Excluding Participants With Mycobacteria Infections From Clinical Trials: A Critical Consideration in Evaluating the Efficacy of BCG Against COVID-19 [J].
Gong, Wenping ;
Du, Jingli .
JOURNAL OF KOREAN MEDICAL SCIENCE, 2023, 38 (42)